FMR1 and fragile X syndrome: The FMR1 FM mRNA toxicity mechanism does not apply to FMR1 KO animal models, while it may have significant implications for the behavioural phenotype in patients affected with FXS, especially because behavioural phenotypes were targeted by most primary outcome measures in the recent clinical trials [43, 44].